Loading data for CDT — first visit, this takes a few seconds.
CDT Equity Inc. (CDT)
NasdaqCM: CDT
· 即時價格 · USD
0.63
-0.12 (-16.00%)
收盤價： Sep 04, 2026, 8:00 PM
0.64
+2.70%
盤後: 7:59 PM
股價、關鍵數字和最新消息，都在這一頁。
CDT Equity Inc.（CDT）股價、分析與資料
無可用資料
| 買價 | 0.62 |
| 市值 | 8.56M |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -37.1M |
| 1.45 | |
| -2545.36 | |
| n/a | |
| n/a | |
| P/B (ttm) | 0.00 |
| P/S (ttm) | 0.00 |
| 財報日期 | Nov 12, 2025 |
| 賣價 | 1.14 |
| 成交量 | 720,247 |
| 20 日平均成交量 | 747,449 |
| 開盤價 | 0.73 |
| 前收盤價 | 0.75 |
| 當日區間 | 0.61 - 0.73 |
| 52 週範圍 | 0.61 - 2360.00 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 CDT
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, wh...
完整的公司簡介財報驚奇
CDT Equity 已於 Invalid Date 公布季度財報：
- 營收為 n/a 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 低於預期 , 年增 NaN% 成長.
